PL3004167T3 - Białka wiążące antygen receptora onkostatyny m - Google Patents

Białka wiążące antygen receptora onkostatyny m

Info

Publication number: PL3004167T3
Authority: PL; Poland
Prior art keywords: onkostatin; antigenus; receptor; binding protein; protein
Prior art date: 2013-05-30

Application number

PL14734671T

Other languages

English (en)

Inventor

Heather A. Arnett

Sabine S. Escobar

Chadwick T. King

Ai Ching Lim

Saravanakumar NARAYANAN

Paul H. Weinreb

Nels E. Pederson

Original Assignee

Kiniksa Pharmaceuticals, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-30

Filing date

2014-05-30

Publication date

2019-01-31

2014-05-30 Application filed by Kiniksa Pharmaceuticals, Ltd. filed Critical Kiniksa Pharmaceuticals, Ltd.

2019-01-31 Publication of PL3004167T3 publication Critical patent/PL3004167T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL14734671T 2013-05-30 2014-05-30 Białka wiążące antygen receptora onkostatyny m PL3004167T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361829082P	2013-05-30	2013-05-30
PCT/US2014/040360 WO2014194274A2 (en)	2013-05-30	2014-05-30	Oncostatin m receptor antigen binding proteins
EP14734671.2A EP3004167B1 (en)	2013-05-30	2014-05-30	Oncostatin m receptor antigen binding proteins

Publications (1)

Publication Number	Publication Date
PL3004167T3 true PL3004167T3 (pl)	2019-01-31

Family

ID=51059621

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL14734671T PL3004167T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m
PL21190497.4T PL3971212T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m
PL18185359T PL3456743T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL21190497.4T PL3971212T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m
PL18185359T PL3456743T3 (pl)	2013-05-30	2014-05-30	Białka wiążące antygen receptora onkostatyny m

Country Status (23)

Country	Link
US (7)	US9663571B2 (pl)
EP (4)	EP3971212B1 (pl)
JP (6)	JP6243521B2 (pl)
KR (3)	KR101882366B1 (pl)
CN (4)	CN118271441A (pl)
AU (4)	AU2014273966B2 (pl)
BR (1)	BR112015029643B1 (pl)
CA (1)	CA2910732A1 (pl)
DK (2)	DK3456743T3 (pl)
EA (1)	EA201592285A1 (pl)
ES (3)	ES2895824T3 (pl)
HU (2)	HUE056580T2 (pl)
IL (3)	IL317484A (pl)
MX (3)	MX351127B (pl)
MY (1)	MY199321A (pl)
NZ (2)	NZ753995A (pl)
PL (3)	PL3004167T3 (pl)
PT (2)	PT3004167T (pl)
SG (1)	SG11201508829QA (pl)
SI (2)	SI3004167T1 (pl)
TR (1)	TR201815608T4 (pl)
WO (1)	WO2014194274A2 (pl)
ZA (1)	ZA201508064B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101882366B1 (ko)	2013-05-30	2018-07-30	키닉사 파마슈티컬스, 리미티드	온코스타틴 m 수용체 항원 결합 단백질
US10822406B2 (en)	2015-01-29	2020-11-03	Oxford University Innovation Limited	Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR)
WO2018005954A2 (en)	2016-07-01	2018-01-04	Resolve Therapeutics, Llc	Optimized binuclease fusions and methods
WO2018156180A1 (en)	2017-02-24	2018-08-30	Kindred Biosciences, Inc.	Anti-il31 antibodies for veterinary use
BR112019021364A2 (pt) *	2017-04-11	2020-05-05	Kiniksa Phamaceuticals Ltd	formulação estável de anticorpo anti-osmr
MX2020002070A (es)	2017-08-22	2020-03-24	Sanabio Llc	Receptores solubles de interferon y usos de los mismos.
AU2019276779A1 (en) *	2018-04-25	2020-12-10	Kiniksa Pharmaceuticals, Ltd.	Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
WO2020036833A1 (en) *	2018-08-13	2020-02-20	Kiniksa Pharmaceuticals, Ltd.	Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
EP3877408A4 (en) *	2018-11-06	2022-08-24	University of Miami	COMPOSITIONS AND PRODUCTION OF RECOMBINANT AAV VIRUS VECTORS CAPABLE OF IN VIVO GLYCOENGINEERING
CN110563844A (zh) *	2019-09-04	2019-12-13	华中农业大学	一种抗犬白介素31受体的多克隆抗体及其应用
MX2023004500A (es) *	2020-10-19	2023-05-10	Zoetis Services Llc	Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos.
IL310551A (en) *	2021-07-30	2024-03-01	Univ Texas	Monoclonal antibodies specific for OSMR and methods of using them
WO2024002259A1 (zh) *	2022-06-29	2024-01-04	百奥赛图(北京)医药科技股份有限公司	一种osm、osmr、il31ra和/或il31基因修饰的非人动物
TW202444755A (zh)	2023-03-07	2024-11-16	美商建南德克公司	治療肺纖維化疾病或病症之方法
TW202515615A (zh) *	2023-09-01	2025-04-16	美商建南德克公司	治療發炎性腸病之方法
CN120230206A (zh) *	2023-12-29	2025-07-01	苏州爱科百发生物医药技术有限公司	抑瘤素M受体β结合抗体及其用途

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4447A (en)		1846-04-04		Car- wheel
US233A (en)		1837-06-14		Improvement in plows
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US3896111A (en)	1973-02-20	1975-07-22	Research Corp	Ansa macrolides
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4151042A (en)	1977-03-31	1979-04-24	Takeda Chemical Industries, Ltd.	Method for producing maytansinol and its derivatives
US4137230A (en)	1977-11-14	1979-01-30	Takeda Chemical Industries, Ltd.	Method for the production of maytansinoids
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
US4265814A (en)	1978-03-24	1981-05-05	Takeda Chemical Industries	Matansinol 3-n-hexadecanoate
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4307016A (en)	1978-03-24	1981-12-22	Takeda Chemical Industries, Ltd.	Demethyl maytansinoids
JPS5562090A (en)	1978-10-27	1980-05-10	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
US4256746A (en)	1978-11-14	1981-03-17	Takeda Chemical Industries	Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS5566585A (en)	1978-11-14	1980-05-20	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55102583A (en)	1979-01-31	1980-08-05	Takeda Chem Ind Ltd	20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS55164685A (en)	1979-06-08	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4309428A (en)	1979-07-30	1982-01-05	Takeda Chemical Industries, Ltd.	Maytansinoids
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
EP0028683A1 (en)	1979-09-21	1981-05-20	Takeda Chemical Industries, Ltd.	Antibiotic C-15003 PHO and production thereof
JPS5645485A (en)	1979-09-21	1981-04-25	Takeda Chem Ind Ltd	Production of c-15003pnd
WO1982001188A1 (en)	1980-10-08	1982-04-15	Takeda Chemical Industries Ltd	4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en)	1980-11-03	1984-05-22	Standard Oil Company	Impact improvement of high nitrile resins
US4313946A (en)	1981-01-27	1982-02-02	The United States Of America As Represented By The Secretary Of Agriculture	Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en)	1981-01-27	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Method of controlling the European corn borer with trewiasine
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4475196A (en)	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
DE3675588D1 (de)	1985-06-19	1990-12-20	Ajinomoto Kk	Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5681930A (en)	1985-12-20	1997-10-28	Bristol-Myers Squibb Company	Anti-oncostatin M monoclonal antibodies
EP0272253A4 (en)	1986-03-07	1990-02-05	Massachusetts Inst Technology	METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4965195A (en)	1987-10-26	1990-10-23	Immunex Corp.	Interleukin-7
US4968607A (en)	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
WO1990005183A1 (en)	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6291158B1 (en)	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertoire
US5683888A (en)	1989-07-22	1997-11-04	University Of Wales College Of Medicine	Modified bioluminescent proteins and their use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5292658A (en)	1989-12-29	1994-03-08	University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center	Cloning and expressions of Renilla luciferase
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
ZA912136B (en) *	1990-03-29	1992-11-25	Bristol Myers Squibb Co	Anti-oncostatin m monoclonal antibodies
WO1991018982A1 (en)	1990-06-05	1991-12-12	Immunex Corporation	Type ii interleukin-1 receptors
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
DE69131780T2 (de)	1991-03-11	2000-11-16	University Of Georgia Research Foundation, Athens	Klonierung und expression der luziferase aus renilla
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
ATE463573T1 (de)	1991-12-02	2010-04-15	Medimmune Ltd	Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ES2149768T3 (es)	1992-03-25	2000-11-16	Immunogen Inc	Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US6239328B1 (en)	1992-10-05	2001-05-29	North Carolina State University	Method for reducing expression variability of transgenes in plant cells
DK0672141T3 (da)	1992-10-23	2003-06-10	Immunex Corp	Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
CA2150262C (en)	1992-12-04	2008-07-08	Kaspar-Philipp Holliger	Multivalent and multispecific binding proteins, their manufacture and use
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
AU694745B2 (en)	1993-09-10	1998-07-30	Trustees Of Columbia University In The City Of New York, The	Uses of green fluorescent protein
WO1995021191A1 (en)	1994-02-04	1995-08-10	William Ward	Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5783672A (en)	1994-05-26	1998-07-21	Immunex Corporation	Receptor for oncostatin M
US5777079A (en)	1994-11-10	1998-07-07	The Regents Of The University Of California	Modified green fluorescent proteins
US5874304A (en)	1996-01-18	1999-02-23	University Of Florida Research Foundation, Inc.	Humanized green fluorescent protein genes and methods
US5804387A (en)	1996-02-01	1998-09-08	The Board Of Trustees Of The Leland Stanford Junior University	FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en)	1996-02-06	1999-03-02	Bryan; Bruce	Bioluminescent novelty items
US5925558A (en)	1996-07-16	1999-07-20	The Regents Of The University Of California	Assays for protein kinases using fluorescent protein substrates
US6037525A (en)	1996-08-01	2000-03-14	North Carolina State University	Method for reducing expression variability of transgenes in plant cells
US5976796A (en)	1996-10-04	1999-11-02	Loma Linda University	Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DK1500329T3 (da)	1996-12-03	2012-07-09	Amgen Fremont Inc	Humane antistoffer, der specifikt binder TNF-alfa
AU741076B2 (en)	1996-12-12	2001-11-22	Prolume, Ltd.	Apparatus and method for detecting and identifying infectious agents
US6245974B1 (en)	1997-08-06	2001-06-12	North Carolina State University	Matrix attachment regions
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
GB9806530D0 (en)	1998-03-26	1998-05-27	Glaxo Group Ltd	Inflammatory mediator
EP1064360B1 (en)	1998-03-27	2008-03-05	Prolume, Ltd.	Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
US6177612B1 (en)	1998-07-31	2001-01-23	Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada	Matrix attachment regions
EP1117815A1 (en)	1998-09-29	2001-07-25	Pioneer Hi-Bred International Inc.	Mar/sar elements flanking rsyn7-driven construct
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2003514903A (ja)	1999-11-24	2003-04-22	イムノージェンインコーポレーテッド	タキサンを含有する細胞傷害薬とその治療への利用
US20030096339A1 (en)	2000-06-26	2003-05-22	Sprecher Cindy A.	Cytokine receptor zcytor17
KR100408844B1 (ko)	2000-07-29	2003-12-06	한국산업기술평가원	동물세포 발현벡터
US6333410B1 (en)	2000-08-18	2001-12-25	Immunogen, Inc.	Process for the preparation and purification of thiol-containing maytansinoids
WO2002048379A1 (en)	2000-12-15	2002-06-20	Pangen Biotech Inc.	Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
ATE437233T1 (de)	2001-01-26	2009-08-15	Selexis Sa	Matrix-anheftungsregionen und verfahren zu deren verwendung
JP4303105B2 (ja)	2001-06-28	2009-07-29	ドマンティスリミテッド	二重特異性リガンドとその利用
US7230167B2 (en)	2001-08-31	2007-06-12	Syngenta Participations Ag	Modified Cry3A toxins and nucleic acid sequences coding therefor
CN101843895A (zh)	2002-01-18	2010-09-29	津莫吉尼蒂克斯公司	新的细胞因子zcytor17配体
AU2003280410B8 (en)	2002-01-18	2009-04-23	Zymogenetics, Inc.	Cytokine receptor zcytor17 multimers
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
EP1517921B1 (en)	2002-06-28	2006-06-07	Domantis Limited	Dual specific ligands with increased serum half-life
ES2361739T3 (es)	2002-08-16	2011-06-21	Immunogen, Inc.	Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
JP2006523090A (ja)	2002-12-27	2006-10-12	ドマンティスリミテッド	リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
US7755007B2 (en)	2003-04-17	2010-07-13	K&H Manufacturing, Inc	Heated pet mat
JP2007510434A (ja)	2003-11-12	2007-04-26	シェーリング　コーポレイション	多重遺伝子発現のためのプラスミドシステム
US7235641B2 (en)	2003-12-22	2007-06-26	Micromet Ag	Bispecific antibodies
JP4803789B2 (ja) *	2004-02-03	2011-10-26	独立行政法人科学技術振興機構	疼痛を処置するための薬学的組成物
ES2533695T3 (es)	2004-03-02	2015-04-14	Seattle Genetics, Inc.	Anticuerpos cargados parcialmente y métodos para su conjugación
PE20060287A1 (es)	2004-03-30	2006-05-16	Glaxo Group Ltd	INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM
KR101200133B1 (ko)	2004-06-01	2012-11-13	제넨테크, 인크.	항체 약물 접합체 및 방법
WO2006065533A2 (en)	2004-11-29	2006-06-22	Seattle Genetics, Inc.	Engineered antibodies and immunoconjugates
US7301019B2 (en)	2005-01-21	2007-11-27	Immunogen, Inc.	Method for the preparation of maytansinoid esters
JP5328156B2 (ja) *	2005-02-03	2013-10-30	マクロジェニックスウエスト，インコーポレイテッド	オンコスタチンｍレセプターに対する抗体
JP2008530132A (ja)	2005-02-14	2008-08-07	ザイモジェネティクス，インコーポレイテッド	Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
WO2006122079A1 (en)	2005-05-06	2006-11-16	Zymogenetics, Inc.	Il-31 monoclonal antibodies and methods of use
US8101183B2 (en)	2005-05-06	2012-01-24	Zymogentics, Inc.	Variable region sequences of IL-31 monoclonal antibodies
JP5053264B2 (ja)	2005-05-19	2012-10-17	アムジェンインコーポレイテッド	抗体の安定性を増加させるための組成物および方法
CN101217979A (zh)	2005-06-14	2008-07-09	安姆根有限公司	自缓冲蛋白制剂
EA014513B1 (ru)	2005-08-03	2010-12-30	Иммьюноджен, Инк.	Композиция иммуноконъюгата
ATE535529T1 (de)	2005-08-09	2011-12-15	Millennium Pharm Inc	Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
WO2007133816A2 (en) *	2006-01-10	2007-11-22	Zymogenetics, Inc.	Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
JP5349058B2 (ja)	2006-03-01	2013-11-20	トムソンライセンシング	メディア・パッケージを生成するためのデバイスおよび方法
GEP20125628B (en)	2006-04-21	2012-09-10	Novartis Ag	Pharmaceutical compositions containing antagonist anti-cd40 antibody
SI2047863T1 (sl)	2006-06-08	2013-11-29	Chugai Seiyaku Kabushiki Kaisha	Sredstvo za preprečevanje ali zdravljenje vnetne bolezni
JP2010502652A (ja)	2006-09-01	2010-01-28	ザイモジェネティクス，インコーポレイティド	Ｉｌ−３１モノクローナル抗体の可変領域配列と使用方法
US8247537B2 (en) *	2006-11-15	2012-08-21	Medarex, Inc.	Human monoclonal antibodies to BTLA and methods of use
KR101486615B1 (ko)	2007-07-16	2015-01-28	제넨테크, 인크.	항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
US7695963B2 (en)	2007-09-24	2010-04-13	Cythera, Inc.	Methods for increasing definitive endoderm production
CA2708251C (en)	2007-12-07	2016-04-12	Zymogenetics, Inc.	Humanized antibody molecules specific for il-31
DK2235064T3 (en)	2008-01-07	2016-01-11	Amgen Inc	A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
RU2553566C2 (ru)	2008-01-31	2015-06-20	Дженентек, Инк.	АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
LT2281006T (lt)	2008-04-30	2017-11-27	Immunogen, Inc.	Skersinių jungčių linkeriai ir jų panaudojimas
US20120100140A1 (en)	2009-01-23	2012-04-26	Biogen Idec Ma Inc.	Stabilized fc polypeptides with reduced effector function and methods of use
AR080428A1 (es)	2010-01-20	2012-04-11	Chugai Pharmaceutical Co Ltd	Formulaciones liquidas estabilizadas contentivas de anticuerpos
RS61082B1 (sr)	2010-02-26	2020-12-31	Novo Nordisk As	Stabilno antitelo koje sadrži kompozicije
US9475876B2 (en)	2012-05-11	2016-10-25	Wakayama Medical University	Anti oncostatin M receptor beta antibody used for treating atopic dermatitis
WO2013180295A1 (ja)	2012-06-01	2013-12-05	日本電信電話株式会社	パケット転送処理方法およびパケット転送処理装置
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
KR101882366B1 (ko)	2013-05-30	2018-07-30	키닉사 파마슈티컬스, 리미티드	온코스타틴 m 수용체 항원 결합 단백질
US9550828B2 (en)	2013-09-05	2017-01-24	Boise State University	Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US9209965B2 (en)	2014-01-14	2015-12-08	Microsemi Semiconductor Ulc	Network interface with clock recovery module on line card
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof
EP3589318A1 (en)	2017-03-01	2020-01-08	MedImmune Limited	Formulations of monoclonal antibodies
BR112019021364A2 (pt)	2017-04-11	2020-05-05	Kiniksa Phamaceuticals Ltd	formulação estável de anticorpo anti-osmr

2014
- 2014-05-30 KR KR1020157034312A patent/KR101882366B1/ko active Active
- 2014-05-30 ES ES18185359T patent/ES2895824T3/es active Active
- 2014-05-30 CN CN202410270260.4A patent/CN118271441A/zh active Pending
- 2014-05-30 MX MX2015016304A patent/MX351127B/es active IP Right Grant
- 2014-05-30 IL IL317484A patent/IL317484A/en unknown
- 2014-05-30 AU AU2014273966A patent/AU2014273966B2/en active Active
- 2014-05-30 PL PL14734671T patent/PL3004167T3/pl unknown
- 2014-05-30 PL PL21190497.4T patent/PL3971212T3/pl unknown
- 2014-05-30 WO PCT/US2014/040360 patent/WO2014194274A2/en not_active Ceased
- 2014-05-30 PL PL18185359T patent/PL3456743T3/pl unknown
- 2014-05-30 PT PT14734671T patent/PT3004167T/pt unknown
- 2014-05-30 KR KR1020217015688A patent/KR102652165B1/ko active Active
- 2014-05-30 SG SG11201508829QA patent/SG11201508829QA/en unknown
- 2014-05-30 IL IL287824A patent/IL287824B2/en unknown
- 2014-05-30 EA EA201592285A patent/EA201592285A1/ru unknown
- 2014-05-30 BR BR112015029643-2A patent/BR112015029643B1/pt active IP Right Grant
- 2014-05-30 EP EP21190497.4A patent/EP3971212B1/en active Active
- 2014-05-30 NZ NZ753995A patent/NZ753995A/en active IP Right Revival
- 2014-05-30 KR KR1020187021007A patent/KR102258460B1/ko active Active
- 2014-05-30 TR TR2018/15608T patent/TR201815608T4/tr unknown
- 2014-05-30 US US14/891,491 patent/US9663571B2/en active Active
- 2014-05-30 SI SI201430916T patent/SI3004167T1/sl unknown
- 2014-05-30 CN CN201710655839.2A patent/CN107513105B/zh active Active
- 2014-05-30 MY MYPI2018002718A patent/MY199321A/en unknown
- 2014-05-30 ES ES14734671.2T patent/ES2692657T3/es active Active
- 2014-05-30 EP EP14734671.2A patent/EP3004167B1/en active Active
- 2014-05-30 SI SI201431906T patent/SI3456743T1/sl unknown
- 2014-05-30 CA CA2910732A patent/CA2910732A1/en active Pending
- 2014-05-30 HU HUE18185359A patent/HUE056580T2/hu unknown
- 2014-05-30 NZ NZ713636A patent/NZ713636A/en active IP Right Revival
- 2014-05-30 MX MX2017012700A patent/MX380702B/es unknown
- 2014-05-30 PT PT18185359T patent/PT3456743T/pt unknown
- 2014-05-30 DK DK18185359.9T patent/DK3456743T3/da active
- 2014-05-30 ES ES21190497T patent/ES2973474T3/es active Active
- 2014-05-30 JP JP2016517062A patent/JP6243521B2/ja active Active
- 2014-05-30 EP EP23210981.9A patent/EP4349864A3/en active Pending
- 2014-05-30 DK DK14734671.2T patent/DK3004167T3/en active
- 2014-05-30 HU HUE14734671A patent/HUE040548T2/hu unknown
- 2014-05-30 CN CN201480031080.5A patent/CN105555803B/zh active Active
- 2014-05-30 EP EP18185359.9A patent/EP3456743B1/en active Active
- 2014-05-30 CN CN201910733125.8A patent/CN110511279B/zh active Active
2015
- 2015-10-30 ZA ZA2015/08064A patent/ZA201508064B/en unknown
- 2015-11-26 MX MX2020003503A patent/MX2020003503A/es unknown
2016
- 2016-09-28 US US15/279,305 patent/US9593163B2/en active Active
2017
- 2017-04-12 US US15/486,094 patent/US9738721B1/en active Active
- 2017-05-29 JP JP2017105838A patent/JP6606122B2/ja active Active
- 2017-07-11 US US15/646,699 patent/US10421813B2/en active Active
- 2017-09-15 AU AU2017228686A patent/AU2017228686B2/en active Active
2019
- 2019-06-16 IL IL267382A patent/IL267382B/en unknown
- 2019-08-07 US US16/534,900 patent/US20190359724A1/en not_active Abandoned
- 2019-10-17 JP JP2019189968A patent/JP2020022482A/ja active Pending
2020
- 2020-02-11 AU AU2020200980A patent/AU2020200980B2/en active Active
2021
- 2021-09-03 US US17/466,395 patent/US12122837B2/en active Active
2022
- 2022-04-14 AU AU2022202503A patent/AU2022202503B2/en active Active
- 2022-09-27 JP JP2022153731A patent/JP7474817B2/ja active Active
2024
- 2024-04-15 JP JP2024065396A patent/JP7682335B2/ja active Active
- 2024-09-19 US US18/890,024 patent/US20250230250A1/en active Pending
2025
- 2025-05-13 JP JP2025080667A patent/JP2025114801A/ja active Pending

Also Published As

Publication number	Publication date
CA2910732A1 (en)	2014-12-04
AU2020200980A1 (en)	2020-02-27
PL3971212T3 (pl)	2024-05-27
ZA201508064B (en)	2019-07-31
US12122837B2 (en)	2024-10-22
US20170218076A1 (en)	2017-08-03
CN105555803A (zh)	2016-05-04
IL287824B2 (en)	2025-05-01
EP4349864A3 (en)	2024-06-26
CN105555803B (zh)	2019-09-10
ES2692657T3 (es)	2018-12-04
ES2895824T3 (es)	2022-02-22
HK1249522A1 (zh)	2018-11-02
US20160137739A1 (en)	2016-05-19
WO2014194274A3 (en)	2015-03-12
US9738721B1 (en)	2017-08-22
PT3004167T (pt)	2018-11-13
EA201592285A1 (ru)	2016-05-31
US20190359724A1 (en)	2019-11-28
EP3456743B1 (en)	2021-08-18
JP7682335B2 (ja)	2025-05-23
DK3456743T3 (da)	2021-09-27
KR20180086295A (ko)	2018-07-30
MX2020003503A (es)	2020-07-22
JP7474817B2 (ja)	2024-04-25
JP2017140056A (ja)	2017-08-17
AU2022202503B2 (en)	2025-08-14
US20180002429A1 (en)	2018-01-04
HUE040548T2 (hu)	2019-03-28
JP2024095814A (ja)	2024-07-10
HK1224310A1 (zh)	2017-08-18
AU2022202503A1 (en)	2022-05-12
US20250230250A1 (en)	2025-07-17
BR112015029643B1 (pt)	2023-12-12
DK3004167T3 (en)	2018-11-12
PT3456743T (pt)	2021-10-27
CN118271441A (zh)	2024-07-02
KR102652165B1 (ko)	2024-03-27
MX2015016304A (es)	2016-03-21
KR102258460B1 (ko)	2021-06-02
SI3004167T1 (sl)	2019-01-31
JP6606122B2 (ja)	2019-11-13
JP2020022482A (ja)	2020-02-13
EP3004167A2 (en)	2016-04-13
IL287824B1 (en)	2025-01-01
CN110511279B (zh)	2024-03-29
EP3456743A1 (en)	2019-03-20
AU2014273966B2 (en)	2017-08-31
JP6243521B2 (ja)	2017-12-06
TR201815608T4 (tr)	2018-11-21
CN107513105B (zh)	2019-08-16
US9663571B2 (en)	2017-05-30
JP2022180573A (ja)	2022-12-06
MX351127B (es)	2017-10-03
JP2016520619A (ja)	2016-07-14
WO2014194274A2 (en)	2014-12-04
IL267382B (en)	2021-12-01
JP2025114801A (ja)	2025-08-05
CN110511279A (zh)	2019-11-29
US9593163B2 (en)	2017-03-14
EP4349864A2 (en)	2024-04-10
EP3971212C0 (en)	2023-12-27
SI3456743T1 (sl)	2022-01-31
US20170008958A1 (en)	2017-01-12
KR20160011644A (ko)	2016-02-01
HUE056580T2 (hu)	2022-02-28
KR20210064400A (ko)	2021-06-02
US20220056144A1 (en)	2022-02-24
MX380702B (es)	2025-03-12
AU2017228686A1 (en)	2017-10-05
EP3971212A1 (en)	2022-03-23
MY199321A (en)	2023-10-24
AU2017228686B2 (en)	2019-11-14
NZ753995A (en)	2022-07-01
EP3004167B1 (en)	2018-07-25
NZ713636A (en)	2022-07-01
AU2020200980B2 (en)	2022-04-28
EP3971212B1 (en)	2023-12-27
ES2973474T3 (es)	2024-06-20
AU2014273966A1 (en)	2015-11-12
CN107513105A (zh)	2017-12-26
KR101882366B1 (ko)	2018-07-30
IL267382A (en)	2019-08-29
HK1221961A1 (en)	2017-06-16
IL287824A (en)	2022-01-01
BR112015029643A2 (pt)	2017-09-26
IL317484A (en)	2025-02-01
US10421813B2 (en)	2019-09-24
SG11201508829QA (en)	2015-12-30
PL3456743T3 (pl)	2022-03-07

Publication	Publication Date	Title
PL3004167T3 (pl)	2019-01-31	Białka wiążące antygen receptora onkostatyny m
DK2970464T3 (da)	2020-08-03	Anti-lag-3-bindende proteiner
CL2016000680A1 (es)	2016-12-23	Formulaciones de anticuerpos anti-pdl1.
FR3006466B3 (fr)	2015-10-30	.
DK3736291T5 (da)	2024-08-26	Anti-FCRH5-antistoffer
DK3242892T3 (da)	2022-01-24	Modificerede april-bindende antistoffer
DK2951203T3 (da)	2019-08-12	Heterodimere proteiner
DK3708583T3 (da)	2022-05-16	Ikke-fucosylerede anti-fgfr2iiib-antistoffer
LT3169706T (lt)	2020-03-25	Antikūnai, besirišantys prie axl
BR302014001378S1 (pt)	2015-05-19	Configuração aplicada em bolsa.
HUE051357T2 (hu)	2021-03-01	IL-23 kötõ antitestek
DK3041857T3 (da)	2019-07-22	Protein a-kromatografi
CL2016000219A1 (es)	2016-09-16	Proteinas de fusión terapéutica.
DK3068800T3 (da)	2019-10-21	FcRn-specifikke antistoffer
HUE043273T2 (hu)	2019-08-28	Fúziós fehérje
DK2975030T3 (da)	2020-08-31	Dihydropyridazin-3,5-dion-derivat
DK3055664T3 (da)	2019-06-17	Faldlodsdeflektometer.
HUE048088T2 (hu)	2020-05-28	Új, netrin-1 elleni ellenanyag
FR3007636B1 (fr)	2016-09-02	Trocart perforant.
DK3132031T3 (da)	2021-01-11	Carbohydratbindende protein
DK3065774T3 (da)	2021-08-23	Anti-CCL17-antistoffer
FR3001302B1 (fr)	2016-01-22	.
FR3003394B1 (fr)	2015-03-06	Actionneur magnetothermique.
DK3089990T3 (da)	2020-08-24	Forbedret proteinekspression
FR3001303B1 (fr)	2015-07-31	.